124 related articles for article (PubMed ID: 27935847)
1. Structure-based development of PDEδ inhibitors.
Martín-Gago P; Fansa EK; Wittinghofer A; Waldmann H
Biol Chem; 2017 May; 398(5-6):535-545. PubMed ID: 27935847
[TBL] [Abstract][Full Text] [Related]
2. Small molecule inhibition of the KRAS-PDEδ interaction impairs oncogenic KRAS signalling.
Zimmermann G; Papke B; Ismail S; Vartak N; Chandra A; Hoffmann M; Hahn SA; Triola G; Wittinghofer A; Bastiaens PI; Waldmann H
Nature; 2013 May; 497(7451):638-42. PubMed ID: 23698361
[TBL] [Abstract][Full Text] [Related]
3. Structure guided design and kinetic analysis of highly potent benzimidazole inhibitors targeting the PDEδ prenyl binding site.
Zimmermann G; Schultz-Fademrecht C; Küchler P; Murarka S; Ismail S; Triola G; Nussbaumer P; Wittinghofer A; Waldmann H
J Med Chem; 2014 Jun; 57(12):5435-48. PubMed ID: 24884780
[TBL] [Abstract][Full Text] [Related]
4. PDEδ inhibition impedes the proliferation and survival of human colorectal cancer cell lines harboring oncogenic KRas.
Klein CH; Truxius DC; Vogel HA; Harizanova J; Murarka S; Martín-Gago P; Bastiaens PIH
Int J Cancer; 2019 Feb; 144(4):767-776. PubMed ID: 30194764
[TBL] [Abstract][Full Text] [Related]
5. Discovery of Novel KRAS-PDEδ Inhibitors by Fragment-Based Drug Design.
Chen L; Zhuang C; Lu J; Jiang Y; Sheng C
J Med Chem; 2018 Mar; 61(6):2604-2610. PubMed ID: 29510040
[TBL] [Abstract][Full Text] [Related]
6. Development of Pyridazinone Chemotypes Targeting the PDEδ Prenyl Binding Site.
Murarka S; Martín-Gago P; Schultz-Fademrecht C; Al Saabi A; Baumann M; Fansa EK; Ismail S; Nussbaumer P; Wittinghofer A; Waldmann H
Chemistry; 2017 May; 23(25):6083-6093. PubMed ID: 27809361
[TBL] [Abstract][Full Text] [Related]
7. Discovery of Novel PDEδ Degraders for the Treatment of KRAS Mutant Colorectal Cancer.
Cheng J; Li Y; Wang X; Dong G; Sheng C
J Med Chem; 2020 Jul; 63(14):7892-7905. PubMed ID: 32603594
[TBL] [Abstract][Full Text] [Related]
8. Identification of a new inhibitor of KRAS-PDEδ interaction targeting KRAS mutant nonsmall cell lung cancer.
Leung EL; Luo LX; Li Y; Liu ZQ; Li LL; Shi DF; Xie Y; Huang M; Lu LL; Duan FG; Huang JM; Fan XX; Yuan ZW; Ding J; Yao XJ; Ward DC; Liu L
Int J Cancer; 2019 Sep; 145(5):1334-1345. PubMed ID: 30786019
[TBL] [Abstract][Full Text] [Related]
9. Identification of pyrazolopyridazinones as PDEδ inhibitors.
Papke B; Murarka S; Vogel HA; Martín-Gago P; Kovacevic M; Truxius DC; Fansa EK; Ismail S; Zimmermann G; Heinelt K; Schultz-Fademrecht C; Al Saabi A; Baumann M; Nussbaumer P; Wittinghofer A; Waldmann H; Bastiaens PI
Nat Commun; 2016 Apr; 7():11360. PubMed ID: 27094677
[TBL] [Abstract][Full Text] [Related]
10. EPHA2 feedback activation limits the response to PDEδ inhibition in KRAS-dependent cancer cells.
Chen YH; Lv H; Shen N; Wang XM; Tang S; Xiong B; Ding J; Geng MY; Huang M
Acta Pharmacol Sin; 2020 Feb; 41(2):270-277. PubMed ID: 31316177
[TBL] [Abstract][Full Text] [Related]
11. Structural Biology-Inspired Discovery of Novel KRAS-PDEδ Inhibitors.
Jiang Y; Zhuang C; Chen L; Lu J; Dong G; Miao Z; Zhang W; Li J; Sheng C
J Med Chem; 2017 Nov; 60(22):9400-9406. PubMed ID: 28929751
[TBL] [Abstract][Full Text] [Related]
12. Development of PD3 and PD3-B for PDEδ inhibition to modulate KRAS activity.
Lee J; Lee HJ; Lee Y; Lim B; Gam J; Oh DC; Lee J
J Enzyme Inhib Med Chem; 2022 Dec; 37(1):1656-1666. PubMed ID: 35695156
[TBL] [Abstract][Full Text] [Related]
13. Molecular Simulations of Solved Co-crystallized X-Ray Structures Identify Action Mechanisms of PDEδ Inhibitors.
Salmas RE; Mestanoglu M; Yurtsever M; Noskov SY; Durdagi S
Biophys J; 2015 Sep; 109(6):1163-8. PubMed ID: 26340817
[TBL] [Abstract][Full Text] [Related]
14. Molecular mechanism of the association and dissociation of Deltarasin from the heterodimeric KRas4B-PDEδ complex.
Bello M; Correa-Basurto J; Vargas-Mejía MÁ
Biopolymers; 2019 Nov; 110(11):e23333. PubMed ID: 31568570
[TBL] [Abstract][Full Text] [Related]
15. Arl2-Mediated Allosteric Release of Farnesylated KRas4B from Shuttling Factor PDEδ.
Ozdemir ES; Jang H; Gursoy A; Keskin O; Nussinov R
J Phys Chem B; 2018 Aug; 122(30):7503-7513. PubMed ID: 29961325
[TBL] [Abstract][Full Text] [Related]
16. Development of a PDEδ-Targeting PROTACs that Impair Lipid Metabolism.
Winzker M; Friese A; Koch U; Janning P; Ziegler S; Waldmann H
Angew Chem Int Ed Engl; 2020 Mar; 59(14):5595-5601. PubMed ID: 31829492
[TBL] [Abstract][Full Text] [Related]
17. Dissociation of the K-Ras4B/PDEδ complex upon contact with lipid membranes: membrane delivery instead of extraction.
Weise K; Kapoor S; Werkmüller A; Möbitz S; Zimmermann G; Triola G; Waldmann H; Winter R
J Am Chem Soc; 2012 Jul; 134(28):11503-10. PubMed ID: 22721555
[TBL] [Abstract][Full Text] [Related]
18. Fixing a hole where the Ras gets in.
Iwig JS; Kuriyan J
Cell; 2013 Jun; 153(6):1191-3. PubMed ID: 23746837
[TBL] [Abstract][Full Text] [Related]
19. The KRAS-PDEδ interaction is a therapeutic target.
Cancer Discov; 2013 Jul; 3(7):OF20. PubMed ID: 23847364
[TBL] [Abstract][Full Text] [Related]
20. PDEδ Binding to Ras Isoforms Provides a Route to Proper Membrane Localization.
Muratcioglu S; Jang H; Gursoy A; Keskin O; Nussinov R
J Phys Chem B; 2017 Jun; 121(24):5917-5927. PubMed ID: 28540724
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]